Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Pittock S.; Berthele A.; Fujihara K.; Kim H.; Levy M.; Palace Jacqueline; Nakashima I.; Terzi M.; Totolyan N.; Viswanathan S.; Wang Kai-Chen; Pace A.; Fujita K.; Armstrong R.; Wingerchuk D.

doi:10.1056/nejmoa1900866

← Today's brief

L2 Study

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Pittock S. et al. · The New England journal of medicine · Tuesday, January 1, 2019

Read original

Design Level 2n 143Funding Independent

Source

Pittock S. et al.. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. The New England journal of medicine. Tuesday, January 1, 2019.
doi:10.1056/nejmoa1900866

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.